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Background: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via
direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist
exenatide vs. metformin on endothelial function in patients with obesity and pre-diabetes.
Methods: We performed a randomized, open-label, clinical trial in 50 non-diabetic individuals (mean age
58.5 ± 10.0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired
glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin. Microvascular
endothelial function, assessed by digital reactive hyperemia (reactive hyperemic index: RHI), C-reactive protein (CRP),
circulating oxidized LDL (oxLDL), and vascular cell adhesion molecule-1 (VCAM-1) were measured at baseline and
3-months. Seven subjects with IGT participated in a sub-study comparing the effects of pre-administration of
exenatide and metformin on postprandial endothelial function.
Results: There were no differences for the change in RHI (Δ exenatide: 0.01 ± 0.68 vs. Δ metformin: -0.17 ± 0.72,
P = 0.348), CRP, oxLDL, or VCAM-1 between exenatide and metformin treatment. Triglycerides were reduced more
with exenatide compared to metformin (Δ exenatide: -25.5 ± 45.7 mg/dL vs. Δ metformin: -2.9 ± 22.8 mg/dL,
P = 0.032). In the sub-study, there was no difference in postprandial RHI between exenatide and metformin.
Conclusions: Three months of exenatide therapy had similar effects on microvascular endothelial function, markers
of inflammation, oxidative stress, and vascular activation, as metformin, in patients with obesity and pre-diabetes.
Clinical trials registration: This study is registered on http://www.clinicaltrials.gov/: NCT00546728
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The term pre-diabetes is used to describe individuals
with either impaired fasting glucose (IFG), elevated gly-
cosylated hemoglobin (HbA1c), or impaired glucose tol-
erance (IGT). In parallel with the increase in the
prevalence of obesity, the number of individuals with
pre-diabetes is growing rapidly [1]. In addition to being
predictive of type 2 diabetes mellitus (T2DM), pre-
diabetes is associated with increased risk for developing
cardiovascular disease (CVD) [2,3]. The preferred treat-
ment approach for pre-diabetes is lifestyle modification* Correspondence: kelly105@umn.edu
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reproduction in any medium, provided the oremphasizing healthier eating habits and increased levels
of physical activity, ideally leading to weight-loss. How-
ever, drug therapy is also used to treat pre-diabetes with
the goal of preventing the onset of frank T2DM. Most
prominently, metformin and the peroxisome
proliferator-activated receptor-γ agonists pioglitazone
and rosiglitazone have been shown to attenuate the tran-
sition from pre-diabetes to T2DM [4-6]. Metformin is
perhaps the most widely-used medication to treat pre-
diabetes because of its generally well-accepted safety pro-
file and tendency to help patients maintain or reduce
body weight [5].
The potential cardio-protective effects of medications
should be an important consideration when choosing
drug therapy for pre-diabetes given its association withd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spikes may be particularly attractive since these glucose
excursions are associated with endothelial dysfunction,
inflammation, oxidative stress, and atherosclerosis in
individuals with pre-diabetes [7-12]. In this regard, the
glucagon-like peptide-1 (GLP-1) receptor agonist class
may be an ideal candidate due to its primary mechan-
isms of action: reduction of postprandial glucose via in-
creasing insulin secretion, decreasing glucagon secretion,
and slowing gastric emptying [13], which leads to
improved chronic glycemic control even when used in
combination with other diabetes medications [14,15].
Moreover, evidence suggests that GLP-1 may act directly
on the endothelium to improve endothelial function and
inhibit atherosclerosis [16-21] and may have additional
beneficial cardiovascular effects [22,23].
The effect of GLP-1 receptor agonist treatment on
endothelial function has not been well-described in
humans. Therefore, we performed a randomized, head-
to-head clinical trial comparing the acute and chronic
effects of the GLP-1 receptor agonist exenatide vs. met-
formin on microvascular endothelial function in patients
with obesity and either IFG, elevated HbA1c, or IGT.
We chose metformin as the comparator since it is gener-
ally viewed as a first-line drug therapy in the context of
pre-diabetes and has a strong evidence-base supporting
its use in this condition [5].
Methods
Patient population
Fifty non-diabetic individuals (waist circumference ≥102
cm for men and ≥88 cm for women) with abdominal
obesity and either IFG (fasting glucose ≥100 mg/dL), ele-
vated HbA1c (≥5.7%), or IGT (2-hour glucose ≥140 mg/
dL), were enrolled at two sites from 2007–2010: the Uni-
ted Heart and Vascular Clinic and the International Dia-
betes Center at Park Nicollet. Patients were excluded if
they had T2DM, were not on a stable (≥ 1-month) car-
diovascular medication regimen (e.g., anti-hypertensive
therapy, statins, etc.), had used medications for glycemic
control within 1-month, had previous bariatric surgery,
or had a history of severe gastrointestinal disease, un-
stable angina or heart failure. Patients were recruited
from local medical clinics and through advertisements.
The study protocol was approved by the institutional re-
view board at Copernicus Group IRB, the University of
Minnesota, and the International Diabetes Center at
Park Nicollet and written consent was obtained from all
participants.
Study design
We performed a 3-month, randomized (1:1), open-label,
head-to-head (exenatide vs. metformin) clinical trial.
Following baseline testing, patients were randomlyassigned (blocked randomization to ensure an equal
number per treatment group by site) to treatment with
exenatide or metformin for 3-months. Measurements of
study variables were made at baseline and 3-months. All
testing was performed in the morning after patients had
been fasting for at least 12 hours. A sub-study was per-
formed in seven patients with IGT to evaluate the acute
postprandial (acute glucose challenge) effects of exenatide
and metformin on endothelial function. All partici-
pants in the sub-study underwent testing with pre-
administration of both medications and served as their
own control. The sub-study included two extra visits,
each requiring a standard oral glucose tolerance test
(OGTT) with pre-administration of exenatide (10 mcg,
30-minutes prior to glucose ingestion) during one visit
and metformin (1000 mg, 60-minutes prior to glucose
ingestion) during the other visit. The order of the con-
ditions (exenatide and metformin) was randomized.
The control condition (no drug pre-administration to
establish a baseline) was performed during a third visit
(the main-study baseline visit since all sub-study sub-
jects also participated in the main study).
Exenatide and metformin treatment protocol
Exenatide was initiated at a dose of 5 mcg, BID for 1-
month and up-titrated to 10 mcg, BID for the remaining
2-months. Metformin was initiated at a dose of 500 mg,
BID for 1-month and up-titrated to 1000 mg, BID for
the remaining 2-months. Individuals who did not toler-
ate the higher doses of exenatide and metformin were
allowed to continue the study on the lower doses. Study
medications were withheld on the mornings of the study
visits (except for sub-study visits).
Measurement of clinical variables
Height and weight were obtained using a standard stadi-
ometer and electronic scale, respectively. Body mass
index (BMI) was calculated as weight in kilograms
divided by height in meters squared. Waist circumfer-
ence was obtained at end-expiration and measured mid-
way between the base of the rib cage and the superior
iliac crest. The study was performed at two sites, each
with different technologies to measure body fat. At one
site, total body fat was measured with dual energy x-ray
absorptiometry (N = 35) (Hologic Discovery, Hologic,
Inc., Bedford, MA, USA), and at the other, abdominal
visceral/subcutaneous fat was measured by computed
tomography using the average of slices obtained at L1/
L2 and L4/L5 (N = 14) (Siemens SOMATOM Defin-
ition, Siemens Healthcare, Malvern, PA, USA). Sitting
blood pressure measurements were obtained manually
on the same arm using the same cuff size and equipment
after the patient had been resting quietly for 10 minutes.
Fasting lipid profile, glucose, and insulin assays were






Age (years) 58.4 ± 10.1 58.7 ± 10.0 0.911
Gender (male/female) 7/18 5/20 0.742
BMI (kg/m2) 35.8 ± 7.0 35.3 ± 5.5 0.781
Waist Circumference (cm) 112.3 ± 15.7 111.6 ± 12.5 0.861
Body Fat (%) 44.5 ± 4.9 42.3 ± 6.5 0.264
SBP (mmHg) 125.8 ± 12.3 130.6 ± 17.1 0.260
DBP (mmHg) 75.6 ± 10.0 74.3 ± 9.3 0.620
Cholesterol (mg/dL) 185.0 ± 33.1 187.4 ± 28.7 0.782
LDL-Cholesterol (mg/dL) 101.9 ± 27.2 104.1 ± 26.9 0.777
HDL-Cholesterol (mg/dL) 53.2 ± 14.3 53.8 ± 11.9 0.864
Triglycerides (mg/dL) 137.2 ± 43.0 149.0 ± 58.4 0.419
Glucose (mg/dL) 103.1 ± 9.1 103.2 ± 9.9 0.976
Insulin (mU/L) 9.6 ± 8.1 8.5 ± 4.7 0.538
HOMA-IR 2.5 ± 2.4 2.2 ± 1.4 0.547
CRP (mg/L) 4.3 ± 2.2 4.9 ± 3.2 0.510
OxLDL (U/L) 142.8 ± 66.7 123.7 ± 61.4 0.301
VCAM-1 (ng/mL) 529.1 ± 178.6 495.5 ± 119.9 0.440
RHI 2.03 ± 0.66 2.03 ± 0.57 0.989
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood
pressure; LDL = low density lipoprotein; HDL = high density lipoprotein;
HOMA-IR = homeostasis model assessment for insulin resistance; CRP =
C-reactive protein; OxLDL = oxidized low density lipoprotein; VCAM-1 =
vascular cell adhesion molecule-1; RHI = reactive hyperemic index.
Body fat data were obtained in 35 patients (exenatide N = 17; metformin N = 18)
Data are shown as mean ± standard deviation.
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tics (Minneapolis, Minnesota). Homeostasis model as-
sessment of insulin resistance (HOMA-IR), a surrogate
measure of insulin resistance, was calculated using previ-
ously described methods [24].
Plasma biomarkers
Blood plasma for biomarker analysis was stored at −80°C
until the end of the study at which time all samples were
assayed together. C-reactive protein (CRP) (ALPCO
Diagnostics, Salem, NH, USA), circulating oxidized
LDL (oxLDL) (Mercodia, Inc., Winston-Salem, NC,
USA), and vascular cell adhesion molecule-1 (VCAM-
1) (R&D Systems, Inc., Minneapolis, MN, USA) were
measured by ELISA in the University of Minnesota
Cytokine Reference Laboratory (CLIA licensed).
Endothelial function assessment
Microvascular endothelial function was measured by
digital reactive hyperemia (EndoPAT 2000, Itamar Med-
ical, Caesarea, Israel), an operator-independent method
of quantifying endothelial function. Digital reactive
hyperemia is nitric oxide-dependent [25], associated with
coronary artery blood flow [26] and multiple cardiovas-
cular risk factors [27], and independently predicts future
cardiovascular events [28]. Following 10 minutes of quiet
rest in the supine position, finger probes were placed on
the index fingers of both hands to measure baseline and
reactive hyperemic pulse amplitude. The probes applied
a uniform pressure (10 mmHg less than DBP) on the
fingers, which allowed for the detection of small pulse
volume changes throughout the cardiac cycle. Following
the collection of five minutes of baseline data, a blood
pressure cuff on the upper arm was inflated to a supra-
systolic level for five minutes. Following cuff release, the
change in pulse amplitude during reactive hyperemia
was measured for five minutes. The ratio of the
hyperemic and the baseline pulse amplitude (corrected
for the same ratio on the control finger) was calculated
and expressed as the reactive hyperemic index (RHI).
For the sub-study, RHI was measured at baseline (pre-
OGTT) and 1- and 2-hours during the OGTT.
Statistical analysis
Baseline variables were compared between the exenatide
and metformin groups using independent samples t-
tests. For the main study, 2 X 2 (group X time) analysis
of variance (ANOVA) was used to compare changes in
variables between groups before and after the 3-month
treatment period. The ANOVA interaction term was the
pre-specified analysis of interest. For descriptive pur-
poses, within-group treatment effects were analyzed with
paired samples t-tests. For the sub-study, the area under
the curve (AUC) for glucose, insulin, and RHI wascalculated for each of the three conditions (control, exe-
natide, and metformin) and compared by ANOVA. An
alpha value of 0.05 was used to determine statistical sig-
nificance. Data are presented as mean ± standard devi-
ation. GraphPad Prism version 5.0 (GraphPad Software,
Inc., La Jolla, CA, USA) was used for statistical analyses.
Results
Main study
Fifty patients with abdominal obesity and pre-diabetes
were enrolled. All participants were white. There were
no Hispanic individuals in the exenatide group and two
in the metformin group, which did not differ significantly
(P = 0.490). As shown in Table 1, variables at baseline
were similar between the groups. All but three tolerated
the maximal dose of metformin (1000 mg, BID) and all
but three tolerated the maximal dose of exenatide (10
mcg, BID). Medication compliance for both groups was
excellent (metformin = 96 ± 5%; exenatide = 97 ± 4%).
Table 2 shows the treatment effects by group. There
were no differences in the changes from baseline for RHI
(Δ exenatide: 0.01 ± 0.68 vs. Δ metformin: -0.17 ± 0.72,
P = 0.348) (Figure 1), CRP (Δ exenatide: -0.4 ± 2.2 mg/L
vs. Δ metformin: -0.4 ± 2.2 mg/L, P = 0.987), oxLDL
(Δ exenatide: -0.1 ± 41.5 U/L vs. Δ metformin: -16.5 ±








BMI (kg/m2) −0.4 ± 0.7* −0.8 ± 1.4* −0.4 0.229
Waist Circumference (cm) −1.7 ± 3.5* −3.2 ± 6.2* −1.5 0.285
Body Fat (%) 0.8 ± 1.7 0.8 ± 2.6 0.0 0.939
SBP (mmHg) 0.5 ± 10.2 −5.4 ± 15.3 −5.9 0.114
DBP (mmHg) −0.8 ± 6.9 −2.8 ± 7.3 −2.0 0.322
Cholesterol (mg/dL) −9.2 ± 16.1** −14.6 ± 17.4*** −5.4 0.264
LDL-Cholesterol (mg/dL) −1.1 ± 21.4 −9.9 ± 22.5* −8.8 0.169
HDL-Cholesterol (mg/dL) −1.5 ± 9.7 −1.1 ± 12.8 0.4 0.901
Triglycerides (mg/dL) −2.9 ± 22.8 −25.5 ± 45.7* −22.6 0.032
Glucose (mg/dL) −3.7 ± 9.3 −2.7 ± 9.9 1.0 0.725
Insulin (mU/L) −2.4 ± 4.3** −0.6 ± 2.8 1.8 0.079
HOMA-IR −0.8 ± 1.4* −0.2 ± 0.8 0.6 0.094
CRP (mg/L) −0.4 ± 2.2 −0.4 ± 2.2 0.0 0.987
OxLDL (U/L) −16.5 ± 30.4* −0.1 ± 41.5 16.4 0.123
VCAM-1 (ng/mL) −15.3 ± 101.3 10.4 ± 83.2 25.7 0.336
RHI −0.17 ± 0.72 0.01 ± 0.68 0.18 0.348
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL = low density lipoprotein; HDL = high density lipoprotein; HOMA-IR =
homeostasis model assessment for insulin resistance; CRP = C-reactive protein; OxLDL = oxidized low density lipoprotein; VCAM-1 = vascular cell adhesion
molecule-1; RHI = reactive hyperemic index.
Data are shown as mean ± standard deviation; P-Values represent ANOVA interaction term.
Body fat data were obtained in 35 patients (exenatide N = 17; metformin N = 18).
* denotes P<0.05 for within group treatment effect; ** denotes P<0.01 for within group treatment effect; *** denotes P<0.001 for within group treatment effect.
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83.2 ng/mL vs. Δ metformin: -15.3 ± 101.3 ng/mL, P =
0.336) between exenatide and metformin groups. Trigly-
cerides were reduced more with exenatide compared to
metformin (Δ exenatide: -25.5 ± 45.7 mg/dL vs. Δ met-
formin: -2.9 ± 22.8 mg/dL, P = 0.032). There were no dif-
ferences in any of the other variables including visceral
(pre- and post-exenatide: 201.2 ± 44.4 cm2 to 206.3 ±
44.3 cm2, respectively vs. pre- and post-metformin:
286.6 ± 114.4 cm2 to 278.3 ± 122.8 cm2, P = 0.208) and
subcutaneous (pre- and post-exenatide: 473.9 ± 152.5
cm2 to 457.8 ± 143.1 cm2, respectively vs. pre- and post-Figure 1 Endothelial function before and after 3-months of
treatment with either exenatide or metformin.metformin: 352.6 ± 148.4 cm2 to 349.6 ± 131.4 cm2,
P = 0.448) fat in the subset with computed tomog-
raphy data (not presented in Table 2).
Sub-study
All participants (mean age 47.6 ± 12.8; 4 females, 3
males) in the sub-study had IGT. There was a trend to-
ward a difference in glucose AUC during the OGTT
among the three conditions (control AUC: 7,691 ± 2,925
units, vs. exenatide AUC: 4,382 ± 2,421 units, vs. metfor-
min AUC: 5,859 ± 2,210 units, ANOVA P = 0.076) and
no statistically significant difference in insulin AUC
(control AUC: 5,535 ± 1,838 units, vs. exenatide AUC:
4,543 ± 2,389 units, vs. metformin AUC: 4,084 ± 1,800
units, ANOVA P = 0.410). There was no statistically sig-
nificant difference in postprandial RHI AUC among the
three conditions (control AUC: -10.0 ± 50.5 units, vs.
exenatide AUC: 37.8 ± 51.1 units, vs. metformin AUC:
20.5 ± 47.5 units, ANOVA P = 0.203) (Figure 2).
Discussion
Little is known about the effect of chronic GLP-1 recep-
tor agonist treatment on endothelial function in humans.
The primary finding of the current study is that chronic
treatment with exenatide in patients with obesity and
pre-diabetes has similar effects on microvascular endo-
thelial function, inflammation, oxidative stress, and vas-
cular activation as treatment with metformin. These
Figure 2 Serial endothelial function during the OGTT for
control (no drug pre-administration) and pre-administration of
either exenatide or metformin.
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in non-diabetic youth with severe obesity, which demon-
strated no change in endothelial function with 3-months
of exenatide treatment [29]. In regard to inflammation
and oxidative stress, our results are in contrast to a re-
cent study that demonstrated a rapid anti-inflammatory
and reactive oxygen species suppression effect of exena-
tide in patients with T2DM [30]. The contradictory find-
ings between these studies may be explained by the
different patient populations examined (pre-diabetes vs.
T2DM) and the methods by which inflammation and
oxidative stress were measured (systemic vs. cellular/
molecular). Two other studies have evaluated the effects
of acute, one-time, GLP-1 administration on endothelial
function in patients with IGT and T2DM [9,19].
Nystrom et al. [19] reported that infusion of GLP-1 in a
small number (N = 12) of patients with T2DM and
stable coronary artery disease improved brachial artery
flow-mediated dilation while no improvement was
observed in healthy controls. Koska et al. [9] demon-
strated improved postprandial (high-fat meal) RHI with
pre-administration of exenatide (10 mcg) in patients
with either IGT or T2DM. Taken together, these findings
suggest that improvements in endothelial function with
GLP-1 receptor agonists may be limited to the postpran-
dial setting.
There are many potential explanations for the findings
in this study - the most obvious being that GLP-1 recep-
tor agonists may have minimal or no appreciable effect
on endothelial function and blood flow in individuals
with obesity and pre-diabetes. The lack of improvement
in endothelial function may be related to the relatively
short half-life of exenatide (approximately 2.4 hours)
and the fact that its metabolic effects occur predomin-
antly in the postprandial setting. Alternatively, the treat-
ment period may not have been long enough in this
study to elicit an improvement in endothelial function.Some studies have shown that weight loss and glycemic
control continue to improve well beyond 3-months with
exenatide therapy [31-33]. Another potential explanation
for the lack of improvement in endothelial function is
that, despite the high baseline BMI, body fat, CRP, and
other risk factor levels, the baseline RHI values in these
patients were relatively high (2.03 in both groups), which
may have limited the ability of exenatide to exert a bene-
ficial effect. Therefore, it is possible that results may dif-
fer in other patient populations, such as those with
T2DM who often have significant endothelial dysfunc-
tion. Finally, it is possible that the effects of exenatide on
endothelial function may differ by vascular bed, and that
the microvasculature, which was measured in this study,
is less responsive compared to the conduit arteries.
Evidence exists supporting a role for GLP-1 receptor
agonists having a beneficial effect on postprandial endo-
thelial function. Koska et al. recently reported that pre-
administration of exenatide significantly enhanced endothelial
function following a high-fat meal in individuals with
IGT or newly-diagnosed T2DM [9]. Reductions in post-
prandial triglycerides explained over 60% of the effect of
exenatide on endothelial function improvement, suggest-
ing that the beneficial postprandial vascular effects of
GLP-1 receptor agonists are likely mediated via the low-
ering of triglycerides [9,34]. This may explain the lack of
effect in postprandial endothelial function with exena-
tide observed in our study. Instead of a high-fat meal,
which would be expected to raise postprandial triglycer-
ides, we utilized a glucose-only meal. Although we did
not measure postprandial triglycerides in the current
study, it is unlikely that levels increased very much fol-
lowing the glucose load. Therefore, the current state of
the evidence suggests that improvements in endothelial
function with GLP-1 receptor agonists may be limited to
the postprandial period (0–3 hours) primarily in relation
to a high-fat meal.
Strengths of this study included the randomized/con-
trolled design, the similarities between the exenatide and
metformin groups at baseline, and the fact that subjects
were not using any T2DM medications. Limitations
included the non-blinded design, the lack of a non-treatment
control group, and the small sample size for the sub-
study. Because the mean improvement in postprandial
endothelial function was higher with exenatide com-
pared to metformin and control (albeit non-significantly),
it is possible that significant differences may have been
observed with a larger sample size.
In conclusion, 3-months of exenatide therapy had simi-
lar effects on microvascular endothelial function, mar-
kers of inflammation, oxidative stress, and vascular
activation, as treatment with metformin, in patients with
obesity and pre-diabetes. Improvements in endothelial
function with GLP-1 receptor agonists may be limited to
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sumption of a high-fat meal. Future studies should exam-
ine the vascular effects of combined treatment with a
GLP-1 receptor agonist and metformin, evaluate the
effects in patients with T2DM, utilize treatment periods
longer than 3-months, and evaluate the other vascular
beds (e.g., conduit arteries).
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